ABSK-043

N/A

Report date: 2024/11/15 17:02:33
NME

Base Information

Drug NameABSK-043
Drug Alias NameABSK043
ClassificationSmall molecules > Heterocyclic drugs
Mechanisms of ActionProgrammed death-ligand 1 blockers
TargetsProgrammed death-ligand 1
Therapy Area/IndicationsSolid tumoursCarcinoma, Non-Small-Cell LungEsophageal Neoplasms +[7] 
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryCanadaAustraliaMainland China
CombinationsNo
Global Highest StatusPhase 2 Clinical
Highest Status in ChinaPhase 2 Clinical
Originator CompaniesABbisko Therapeutics Co Ltd
China Registration ClassClass 1 Chemical Drug in China

Develop Information

Active CompaniesABbisko Therapeutics Co LtdRenji Hospital Affiliated To Shanghai Jiaotong University School Of MedicineUniversity Health Network (Uhn)
Inactive CompaniesN/A
Active IndicationsSolid tumoursCarcinoma, Non-Small-Cell LungEsophageal Neoplasms +[6] 
Inactive IndicationsNeoplasms

Other Information

ATC CodeN/A
Related LinksN/A